sellWeak cluster of 2
Jorge DiMartino sold $23k of KRON
Chief Medical Officer & VP at Kronos Bio, Inc.. 17,367 shares at an average of $1.31, traded Dec 12, 2023, filed Dec 13, 2023.
Warning score
23Value
$23k
17,367 shares
Holdings after
327,255
-5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$23k at market
- 0Share of holdings soldSold 5.0% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-058464, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2023 | SOpen-market sale Common Stock | -17,367 | $1.31 | $23k | 327,255 | Dec 13, 2023 |
Related signals
Other insiders at Kronos Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | KRONsell Kronos Bio, Inc. | Deborah Knobelman President & Interim CEO | $22k 24,838 shares | -15% | |
| 54Moderate | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $734k 615,518 shares | +6% | |
| 60Notable | KRONbuy Kronos Bio, Inc. | Norbert W Bischofberger PRESIDENT & CEO | $3.1M 3,005,122 shares | +69% | |
| 30Weak | Kronos Bio, Inc. | Allison Frisbee SR VP, CORP OPERATIONS & LEGAL | $13k 12,105 shares | -6% | |
| 30Weak | Kronos Bio, Inc. | Charles Y Lin SR VP, RESEARCH & DEVELOPMENT | $13k 12,036 shares | -5% | |
| 30Weak | Kronos Bio, Inc. | Elizabeth A Olek SR VP, CLINICAL SCIENCE | $7,765 7,368 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Jorge DiMartino Chief Medical Officer & VP | $14k 12,009 shares | -4% | |
| 30Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $8,718 7,366 shares | -3% | |
| 35Weak | Kronos Bio, Inc. | Barbara Kosacz COO & General Counsel | $13k 10,676 shares | -1% | |
| 23Weak | Kronos Bio, Inc. | Christopher Dinsmore Chief Scientific Officer | $13k 10,032 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.